THERAPY DOSSIER · th-3f1e98dc812c

aqueous extract of Flemingia macrophylla (AFM)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21476211 ↗2011Reported benefit

Hepatoprotective effect of the aqueous extract of Flemingia macrophylla on carbon tetrachloride-induced acute hepatotoxicity in rats through anti-oxidative activities.

RatChemical/toxinSprague-DawleyMaleoral0.5 and 1.0 g/kg

Model: carbon tetrachloride (CCl4)-induced acute liver injury

Flemingia macrophylla extract lowered ALT/AST, attenuated histological injury and restored antioxidant enzymes after CCl4 hepatotoxicity.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…